Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Expenses: 2023-2024

Historic Operating Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $17.0 million.

  • Contineum Therapeutics' Operating Expenses rose 76.18% to $17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $50.9 million, marking a year-over-year increase of 50.03%. This contributed to the annual value of $50.9 million for FY2024, which is 50.03% up from last year.
  • Per Contineum Therapeutics' latest filing, its Operating Expenses stood at $17.0 million for Q4 2024, which was up 31.39% from $13.0 million recorded in Q3 2024.
  • Contineum Therapeutics' 5-year Operating Expenses high stood at $17.0 million for Q4 2024, and its period low was $5.1 million during Q1 2023.
  • Over the past 2 years, Contineum Therapeutics' median Operating Expenses value was $10.4 million (recorded in 2024), while the average stood at $10.6 million.
  • Data for Contineum Therapeutics' Operating Expenses shows a peak YoY increase of 94.13% (in 2024) and a maximum YoY decrease of 1.08% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Contineum Therapeutics' Operating Expenses stood at $9.7 million in 2023, then skyrocketed by 76.18% to $17.0 million in 2024.
  • Its Operating Expenses stands at $17.0 million for Q4 2024, versus $13.0 million for Q3 2024 and $10.9 million for Q2 2024.